Differences in immune-related semaphorin levels in the CSF and serum of newly diagnosed, treatment-naive patients with relapsing–remitting multiple sclerosis: a case–control study - Summary - MDSpire
Advertisement
Differences in immune-related semaphorin levels in the CSF and serum of newly diagnosed, treatment-naive patients with relapsing–remitting multiple sclerosis: a case–control study
To investigate alterations in semaphorins (Sema) 3A, 3F, 4A, 4D, and 7A in newly diagnosed, treatment-naive patients with relapsing–remitting multiple sclerosis (RRMS).
Approach:
Study Design: A prospective case–control study evaluating semaphorin levels in 40 RRMS patients and 40 healthy controls.
Methods: Serum and cerebrospinal fluid (CSF) samples were analyzed using enzyme-linked immunosorbent assay.
Key Findings:
Serum levels of Sema3A, Sema4A, Sema4D, and Sema7A were significantly lower in RRMS patients compared to healthy controls after correction for multiple testing.
OCB count was negatively correlated with serum Sema4A and Sema7A and positively correlated with CSF Sema7A.
Patients with an OCB count ≥12 had lower serum levels of Sema3F, Sema4A, and Sema7A.
Sema4D levels were higher in patients with an IgG index ≥0.7.
Patients with infratentorial lesions had lower serum Sema4A levels and higher CSF Sema4A levels.
Interpretation:
Limitations:
The sample size was limited to 40 patients and 40 controls.
Further studies are needed to confirm findings for Sema3F, Sema4A, and Sema4D.
Conclusion:
The study highlights alterations in semaphorin levels in RRMS, warranting further investigation.
